GNPX - Genprex, Inc.

0.3101
-0.025   -8.030%

Share volume: 2,729,867
Last Updated: 04-07-2025
Pharmaceutical Products/Pharmaceutical Preparations: 0.00%

PREVIOUS CLOSE
CHG
CHG%
$0.34
-0.02
-0.07%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
32%
Profitability 25%
Dept financing 12%
Liquidity 50%
Performance 40%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-28.15%
1 Month
-6.03%
3 Months
-59.78%
6 Months
-11.35%
1 Year
-89.52%
2 Year
-62.09%
Key data
Stock price
$0.31
P/E Ratio 
0.00
DAY RANGE
$0.26 - $0.33
EPS 
-$8.04
52 WEEK RANGE
$0.22 - $4.09
52 WEEK CHANGE
-$89.90
MARKET CAP 
936.277 K
YIELD 
N/A
SHARES OUTSTANDING 
2.589 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
04-15-2025
BETA 
-3.92
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$20,454,749
AVERAGE 30 VOLUME 
$9,643,895
Company detail
CEO: J. Rodney Varner
Region: US
Website: genprex.com
Employees: 20
IPO year: 2018
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes.

Recent news
loading